Search Results - "Pınar Sai̇p"

Rapid drug desensitization for platinum‐based chemotherapy drugs significantly increases peripheral blood IL‐10 levels by Tüzer, Can, Sari, Murat, Aktaş Çetin, Esin, Ak, Naziye, Büyüköztürk, Suna, Çolakoğlu, Bahattin, Mualla Saip, Pınar, Deniz, Günnur, Gelincik, Aslı

Get full text

New biomarkers in peripheral blood of patients with ovarian cancer: high expression levels of miR-16-5p, miR-17-5p, and miR-638 by Saral, Mukaddes Avsar, Tuncer, Seref Bugra, Odemis, Demet Akdeniz, Erdogan, Ozge Sukruoglu, Erciyas, Seda Kilic, Saip, Pınar, Ozel, Sevda, Yazici, Hulya

“…Objectives Ovarian cancer is one of the most fatal gynecologic malignities. miR-16-5p, miR-17-5p, and miR-638 genes were found to have been associated with…”
Get full text

Congratulations to the journal of oncological sciences by Saip, Pınar

Get full text

TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer by Cabioglu, Neslihan, Onder, Semen, Oner, Gizem, Karatay, Hüseyin, Tukenmez, Mustafa, Muslumanoglu, Mahmut, İgci, Abdullah, Eralp, Yeşim, Aydiner, Adnan, Saip, Pınar, Yavuz, Ekrem, Ozmen, Vahit

“…The expression of immune checkpoint receptors (ICRs) on tumor-infiltrating lymphocytes (TILs) is associated with better response to immunotherapies via immune…”
Get full text

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey by Ünal, Çağlar, Özmen, Tolga, Ordu, Çetin, Pilanci, Kezban Nur, İlgün, Ahmet Serkan, Gökmen, Erhan, Almuradova, Elvina, Özdoğan, Mustafa, Güler, Nilüfer, Uras, Cihan, Kara, Halil, Demircan, Orhan, Işık, Selver, Alço, Gül, Saip, Pınar, Aydın, Esra, Duymaz, Tomris, Çelebi, Filiz, Yararbaş, Kanay, Soybir, Gursel, Ozmen, Vahit

“…The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive,…”
Get full text

Abstract P3-02-06: Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group by ERALP, Yeşim, DOĞAN, İzzet, Aksoy, Sercan, ÇAKAR, Burcu, BAŞARAN, Gül, ERCELEP, Özlem, MANDEL, Nil MOLİNAS, KORKMAZ, Taner, GÖKMEN, Erhan, AYDINER, Adnan, SAİP, Pınar

“…Abstract Background: Although HER2 is an aggressive subtype of BC, the outcomes have improved over the past two decades due to advances in targeted therapies…”
Get full text

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression by Dogan, Izzet, Aydin, Esra, Khanmammadov, Nijat, Paksoy, Nail, Saip, Pinar, Aydiner, Adnan

“…The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and…”
Get full text

Clinical significance of serum protease-activated receptor 1 (PAR1) level in patients with breast cancer by Ciftci, Rumeysa, Tas, Faruk, Bilgin, Elif, Keskin, Serkan, Yildiz, Ibrahim, Duranyildiz, Derya, Saip, Pınar, Karanlik, Hasan, Vatansever, Sezai

“…The protease-activated receptor 1 (PAR1) is associated with increased invasiveness of breast cancer (BC) cell lines and its overexpression is significantly…”
Get full text

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG) by İçli, Fikri, Altundağ, Kadri, Akbulut, Hakan, Paydaş, Semra, Başaran, Gül, Saip, Pınar, Doğu, Gamze G., Eralp, Yeşim, Uslu, Rüçhan, Sevinç, Alper, Onur, Handan, Mandel, Nil M., Sezgin, Canfeza, Altınbaş, Mustafa, Güler, Nilüfer, Işıkdoğan, Abdurrahman, Gökmen, Erhan, Uygun, Kazım, Üstüner, Zeki, Yaren, Arzu, Demirkan, Binnaz, Coşkun, Uğur, Ata, Alper, Özkan, Metin, Arican, Ali

“…Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of…”
Get full text

Central nervous system metastasis in gynecologic cancers: Seeking the prognostic factors by Minareci, Yagmur, Ak, Naziye, Tosun, Ozgur Aydın, Sozen, Hamdullah, Saip, Pinar Mualla, Topuz, Samet, Salihoglu, Mehmet Yavuz

“…Central nervous system (CNS) metastasis originating from gynecological cancer is a very rare and late manifestation of the disease. Therefore, there is still…”
Get full text

Outcomes of the patients with metastatic male breast cancer by Dogan, Izzet, Khanmammadov, Nijat, Ozkurt, Selnur, Aydiner, Adnan, Saip, Pinar

“…The goal of this research is to investigate the clinical characteristics and prognosis of men with metastatic breast cancer (mMBC). A retrospective analysis of…”
Get full text

The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience by Eralp, Yeşim, Kılıç, Leyla, Alço, Gül, Başaran, Gül, Doğan, Mutlu, Dinçol, Dilek, Demirci, Senem, İçli, Fikri, Onur, Handan, Saip, Pınar, Haydaroğlu, Ayfer

“…Triple negative breast cancer (TNBC) is generally considered as a poorer prognostic subgroup, with propensity for earlier relapse and visceral involvement. The…”
Get full text

Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life by Sari, Murat, Saip, Pınar

“…Background and Aim: Our retrospective, single-center study aimed at evaluating the efficacy and safety of eribulin in heavily pretreated metastatic breast…”
Get full text

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial by Demir, Atakan, Mandel, Nil Molinas, Paydas, Semra, Demir, Gökhan, Er, Özlem, Turhal, Nazım Serdal, Bavbek, Sevil, Eralp, Yeşim, Saip, Pınar Mualla, Güler, Emine Nilüfer, Aydıner, Adnan, Oyan Uluç, Başak, Kılıçkap, Sadettin, Üskent, Necdet, Karadurmuş, Nuri, Kaplan, Mehmet Ali, Yanmaz, Mustafa Teoman, Demir, Hacer, Alan, Özkan, Korkmaz, Taner, Olgun, Polat, Sönmez Uysal, Özlem, Altundağ, Kadri, Gündüz, Şeyda, Günaldı, Meral, Sarı, Murat, Beypınar, İsmail, Başaran, Gül

“…The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen…”
Get full text

Optimal Cytoreduction is an Independent Prognostic Factor in Ovarian Carcinosarcoma: A Turkish Gynecologic Oncology Group Study by AYHAN, Ali, ÇİÇİN, İrfan, GÖKYER, Ali, SARI, Mustafa Erkan, TURAN, Ahmet Taner, TAŞKIN, Salih, GÜNGÖRDÜK, Kemal, AKBAYIR, Özgür, SAİP, Pınar, ŞAHİN, Hanifi, ÇOBAN, Gonca, TOPUZ, Samet, SELÇUK, İlker, TULUNAY, Gökhan, MEYDANLI, Mehmet Mutlu

Get full text

Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors by Dogan, Izzet, Khanmammadov, Nijat, Yıldız, Anıl, Ahmed, Melin Aydan, Vatansever, Sezai, Saip, Pinar, Aydiner, Adnan

“…The goal of the study was to evaluate the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor (EGFR)-mutant metastatic…”
Get full text

Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer by Cabioglu, Neslihan, Bayram, Aysel, Emiroglu, Selman, Onder, Semen, Karatay, Huseyin, Oner, Gizem, Tukenmez, Mustafa, Muslumanoglu, Mahmut, Igci, Abdullah, Aydiner, Adnan, Saip, Pinar, Yavuz, Ekrem, Ozmen, Vahit

“…Immune checkpoint inhibition, combined with novel biomarkers, may provide alternative pathways for treating chemotherapy-resistant triple-negative breast…”
Get full text

Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer? by Celik, Engin, Kizildag Yirgin, Inci, Goksever Celik, Hale, Engin, Gulgun, Sozen, Hamdullah, Ak, Naziye, Saip, Pınar, Onder, Semen, Topuz, Samet, Salihoglu, Mehmet Y.

“…Aim Endometrial cancer is the most common cancer of the female reproductive tract in the developed countries. There are many risk factors defined for the…”
Get full text

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine by Doğan, İzzet, Paksoy, Nail, Ak, Naziye, Vatansever, Sezai, Saip, Pınar, Aydıner, Adnan

“…The aim was to assess the prognostic variables in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients receiving…”
Get full text

Abstract PS10-44: Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer by Dogan, Izzet, Aydın, Esra, Khanmammadov, Nijat, Aydıner, Adnan, Saip, Pınar

“…Abstract Background: Trastuzumab has been used for HER2 positive breast cancer treatment for more than 20 years. The ratio of HER2 overexpression in breast…”
Get full text